TScan TherapeuticsTCRX
TCRX
About: TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Employees: 199
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
25% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 5 (+1) [Q3]
11% more funds holding
Funds holding: 80 [Q2] → 89 (+9) [Q3]
0.1% more ownership
Funds ownership: 85.81% [Q2] → 85.9% (+0.1%) [Q3]
15% less capital invested
Capital invested by funds: $244M [Q2] → $208M (-$35.5M) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
270%
upside
Avg. target
$13
338%
upside
High target
$15
405%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target | 405%upside $15 | Buy Reiterated | 11 Dec 2024 |
Needham Gil Blum 21% 1-year accuracy 34 / 164 met price target | 270%upside $11 | Buy Reiterated | 11 Dec 2024 |
Financial journalist opinion
Based on 3 articles about TCRX published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14)
Neutral
GlobeNewsWire
2 weeks ago
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced it has been named one of the Top Places to Work in Massachusetts in the 17th annual, employee-based survey from The Boston Globe. The 2024 Top Places to Work issue was published online at Globe.com/TopPlaces and will appear in Globe Magazine on Sunday, December 8, 2024.
Neutral
GlobeNewsWire
2 weeks ago
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial
Negative
Zacks Investment Research
1 month ago
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.24 per share a year ago.
Positive
Zacks Investment Research
1 month ago
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
TScan Therapeutics (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
GlobeNewsWire
1 month ago
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT with reduced intensity conditioning Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, at 8:00 a.m.
Neutral
GlobeNewsWire
2 months ago
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually.
Neutral
GlobeNewsWire
3 months ago
TScan Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
Positive
Seeking Alpha
3 months ago
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology
TScan Therapeutics focuses on TCR-T therapies for cancer and autoimmune diseases, leveraging its ImmunoBank and proprietary ReceptorScan platform. TCRX's pipeline is in the early clinical stages, with multiple near-term catalysts, including promising regulatory designations and potential partnerships. The company's leading candidates, TSC-100 and TSC-101, target AML, MDS, and ALL, with FDA RMAT designation potentially expediting approval.
Negative
Zacks Investment Research
4 months ago
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago.
Charts implemented using Lightweight Charts™